Dale A. Sander is CFO at Humacyte, Inc. (HUMA). They have made 4 open-market trades across 1 company since 2022, most recently 2026-05-18.
CIK 0001878193
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
3 open-market purchases totalling $92K since 2022, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| HUMA | 267,213 | $120K |
Shares reported on the most recent Form 4, priced at the 2026-05-20 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| HUMA | SELL · 10b5-1 | 2026-05-18 | 2026-05-20 | $0.90 | $41K | +53.8% | -7.8% | -36.3% |
| HUMA | BUY | 2025-04-10 | 2025-04-14 | $1.53 | $31K | -1.4% | +28.1% | +69.2% |
| HUMA | SELL | 2024-08-27 | 2024-08-29 | $6.68 | $526K | -7.8% | -11.8% | -28.7% |
| HUMA | BUY | 2022-12-16 | 2022-12-19 | $2.60 | $52K | -6.2% | +13.8% | +19.1% |
| HUMA | BUY | 2022-05-17 | 2022-05-18 | $4.53 | $9K | +24.0% | -14.4% | +17.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.